GLP-1/GIP candidate VK2735 shows reductions in subjects' liver fat content and plasma lipid levels
Outcomes from Viking Therapeutics’ Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial of VK2735 were...
top of page
Browse by category
Search
Browse by tag
bottom of page